MedTrace Logo

Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus

NCT02077309 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2017-04-12

No results posted yet for this study

Summary

Examination of the effect of Linagliptin versus placebo for 6 months on vascular inflammation of the carotic artery and on abdominal adipose tissue inflammation in patients with diabetes mellitus type 2. The effect will be assessed by FDG-PET scan.

Furthermore the effect of Linagliptin on the vessel wall volume of the carotid artery will be assessed by MRI scan and biomarkers of vascular inflammation will be analyzed in blood samples.

Conditions

  • Diabetes Mellitus Type 2 (T2DM)
  • Vascular Inflammation
  • Plaque Morphology

Interventions

DRUG

Linagliptin

DRUG

Placebo

Sponsors & Collaborators

  • RWTH Aachen University

    lead OTHER

Principal Investigators

  • Nikolaus Marx, Univ.-Prof. · Department of Internal Medicine I, RWTH Aachen University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-09-30
Completion
2015-11-30

Countries

  • Germany
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02077309 on ClinicalTrials.gov